Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Hepatic p63 regulates glucose metabolism by repressing SIRT1

  • González Rellán, María Jesús
  • Novoa Deaño, Eva María
  • Silva Lima, Natalia da
  • Rodríguez Murueta, Amaia
  • Veyrat Durebex, Christelle
  • Seoane Ruzo, Samuel
  • Porteiro Couto, Begoña
  • Fernández Fondevila, Marcos
  • Fernández Paz, Uxía
  • Varela Rey, Marta María
  • Senra, Ana
  • Iglesias García, Cristina
  • Escudero Pérez, Adriana
  • Fidalgo Pérez, Miguel Ángel
  • Guallar Artal, Diana
  • Pérez Fernández, Román
  • Prevot, Vincent
  • Schwaninger, Markus
  • López Pérez, Miguel A.
  • Diéguez González, Carlos
  • Coppari, Roberto
  • Frühbeck, Gema
  • Nogueiras Pozo, Rubén
Objective p63 is a transcription factor within the p53 protein family that has key roles in development, differentiation and prevention of senescence, but its metabolic actions remain largely unknown. Herein, we investigated the physiological role of p63 in glucose metabolism. Design We used cell lines and mouse models to genetically manipulate p63 in hepatocytes. We also measured p63 in the liver of patients with obesity with or without type 2 diabetes (T2D). Results We show that hepatic p63 expression is reduced on fasting. Mice lacking the specific isoform TAp63 in the liver (p63LKO) display higher postprandial and pyruvate-induced glucose excursions. These mice have elevated SIRT1 levels, while SIRT1 knockdown in p63LKO mice normalises glycaemia. Overexpression of TAp63 in wild-type mice reduces postprandial, pyruvate-induced blood glucose and SIRT1 levels. Studies carried out in hepatocyte cell lines show that TAp63 regulates SIRT1 promoter by repressing its transcriptional activation. TAp63 also mediates the inhibitory effect of insulin on hepatic glucose production, as silencing TAp63 impairs insulin sensitivity. Finally, protein levels of TAp63 are reduced in obese persons with T2D and are negatively correlated with fasting glucose and homeostasis model assessment index. Conclusions. These results demonstrate that p63 physiologically regulates glucose homeostasis
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis

  • Fernández Fondevila, Marcos
  • Fernández, Uxía
  • Heras Domínguez, Violeta
  • Parracho Martínez, Tamara
  • González Rellán, María Jesús
  • Novoa Deaño, Eva María
  • Porteiro Couto, Begoña
  • Alonso, Cristina
  • Mayo, Rebeca
  • Silva Lima, Natália da
  • Iglesias García, Cristina
  • Filliol, Aveline
  • Senra Viñas, Ana
  • Delgado, Teresa
  • Woodhoo, Ashwin
  • Herrero, Laura
  • Serra, Dolors
  • Prevot, Vincent
  • Schwaninger, Markus
  • López Pérez, Miguel A.
  • Diéguez González, Carlos
  • Millet, Óscar
  • Mato de la Paz, José María
  • Cubero Palero, Francisco Javier
  • Varela Rey, Marta María
  • Iruzubieta, Paula
  • Crespo, Javier
  • Martínez Chantar, María Luz
  • Schwabe, Robert F.
  • Nogueiras Pozo, Rubén
One of the most common types of fibrotic liver occurs in patients with non-alcoholic fatty liver disease (NAFLD), which may develop into non-alcoholic steatohepatitis (NASH). Hepatic stellate cells (HSCs) are the primary fibrogenic cell type activated following liver injury, moving from a quiescent phenotype rich in vitamin A into activated myofibroblast-like cells with proliferative and migratory properties.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function

  • González Rellán, María Jesús
  • Parracho, Tamara
  • Heras, Violeta
  • Rodríguez, Amaia
  • Fernández Fondevila, Marcos
  • Novoa Deaño, Eva María
  • Lima, Natalia
  • Varela Rey, Marta María
  • Senra, Ana
  • Chantada Vázquez, María del Pilar
  • Ameneiro, Cristina
  • Bernardo, Ganeko
  • Fernández-Ramos, David
  • Lopitz-Otsoa, Fernando
  • Bilbao, Jon
  • Guallar Artal, Diana
  • Fidalgo, Miguel
  • Bravo López, Susana Belén
  • Diéguez, Carlos
  • Martínez-Chantar, María Luz
  • Millet, Óscar
  • Mato, José M.
  • Schwaninger, Markus
  • Prevot, Vincent
  • Crespo, Javier
  • Frühbeck, Gema
  • Iruzubieta, Paula
  • Nogueiras Pozo, Rubén
Objective O-GlcNAcylation is a post-translational modification that directly couples the processes of nutrient sensing, metabolism, and signal transduction, affecting protein function and localization, since the O-linked N-acetylglucosamine moiety comes directly from the metabolism of glucose, lipids, and amino acids. The addition and removal of O-GlcNAc of target proteins are mediated by two highly conserved enzymes: O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) and O-GlcNAcase (OGA), respectively. Deregulation of O-GlcNAcylation has been reported to be associated with various human diseases such as cancer, diabetes, and cardiovascular diseases. The contribution of deregulated O-GlcNAcylation to the progression and pathogenesis of NAFLD remains intriguing, and a better understanding of its roles in this pathophysiological context is required to uncover novel avenues for therapeutic intervention. By using a translational approach, our aim is to describe the role of OGT and O-GlcNAcylation in the pathogenesis of NAFLD. Methods We used primary mouse hepatocytes, human hepatic cell lines and in vivo mouse models of steatohepatitis to manipulate O-GlcNAc transferase (OGT). We also studied OGT and O-GlcNAcylation in liver samples from different cohorts of people with NAFLD. Results O-GlcNAcylation was upregulated in the liver of people and animal models with steatohepatitis. Downregulation of OGT in NAFLD-hepatocytes improved diet-induced liver injury in both in vivo and in vitro models. Proteomics studies revealed that mitochondrial proteins were hyper-O-GlcNAcylated in the liver of mice with steatohepatitis. Inhibition of OGT is able to restore mitochondrial oxidation and decrease hepatic lipid content in in vitro and in vivo models of NAFLD. Conclusions These results demonstrate that deregulated hyper-O-GlcNAcylation favors NAFLD progression by reducing mitochondrial oxidation and promoting hepatic lipid accumulation
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Inhibition of hepatic p63 ameliorates steatohepatitis with fibrosis in mice

  • Fernández Fondevila, Marcos
  • Eva Nóvoa Deaño
  • Uxía Fernández Paz
  • Dorta Bouza, Valentina
  • Parracho Martínez, Tamara
  • Kreimeyer, Henriette
  • García Vence, María
  • Chantada Vázquez, María del Pilar
  • Bravo López, Susana Belén
  • Porteiro Couto, Begoña
  • López Cabaleiro, Alba
  • Koning, Mijra
  • Ana Senra
  • Yara Souto Becerra
  • Verheij, Joanne
  • Guallar Artal, Diana
  • Fidalgo Pérez, Miguel Ángel
  • Meijnikman, Abraham S.
  • da Silva Lima, Natalia
  • Diéguez González, Carlos
  • González Rellán, María Jesús
  • Nogueiras Pozo, Rubén
Objective p63 is a transcription factor involved in multiple biological functions. In the liver, the TAp63 isoform induces lipid accumulation in hepatocytes. However, the role of liver TAp63 in the progression of metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis is unknown. Methods We evaluated the hepatic p63 levels in different mouse models of steatohepatitis with fibrosis induced by diet. Next, we used virogenetic approaches to manipulate the expression of TAp63 in adult mice under diet-induced steatohepatitis with fibrosis and characterized the disease condition. Finally, we performed proteomics analysis in mice with overexpression and knockdown of hepatic TAp63. Results Levels of TAp63, but not of ΔN isoform, are increased in the liver of mice with diet-induced steatohepatitis with fibrosis. Both preventive and interventional strategies for the knockdown of hepatic TAp63 significantly ameliorated diet-induced steatohepatitis with fibrosis in mice fed a methionine- and choline-deficient diet (MCDD) and choline deficient and high fat diet (CDHFD). The overexpression of hepatic TAp63 in mice aggravated the liver condition in mice fed a CDHFD. Proteomic analysis in the liver of these mice revealed alteration in multiple proteins and pathways, such as oxidative phosphorylation, antioxidant activity, peroxisome function and LDL clearance. Conclusions These results indicate that liver TAp63 plays a critical role in the progression of diet-induced steatohepatitis with fibrosis, and its inhibition ameliorates the disease
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Small extracellular vesicle targeting of hypothalamic AMPKα1 promotes weight loss in leptin receptor deficient mice

  • Milbank, Edward
  • Dragano, Nathalia
  • Vidal Gómez, Xavi
  • Rivas Limeres, Verónica
  • Garrido Gil, Pablo
  • Wertheimer, Mireille
  • Recoquillon, Sylvain
  • Pata, María P.
  • Labandeira García, José Luis
  • Diéguez González, Carlos
  • Nogueiras Pozo, Rubén
  • Martínez, Marie Carmen
  • Andriantsitohaina, Ramaroson
  • López Pérez, Miguel A.
Background and aims: Leptin receptor (LEPR) deficiency promotes severe obesity and metabolic disorders. However, the current therapeutic options against this syndrome are scarce. Methods: db/db mice and their wildtypes were systemically treated with neuronal-targeted small extracellular vesicles (sEVs) harboring a plasmid encoding a dominant negative mutant of AMP-activated protein kinase alpha 1 (AMPKα1-DN) driven by steroidogenic factor 1 (SF1) promoter; this approach allowed to modulate AMPK activity, specifically in SF1 cells of the ventromedial nucleus of the hypothalamus (VMH). Animals were metabolically phenotyped. Results: db/db mice intravenously injected with SF1-AMPKα1-DN loaded sEVs showed a marked feeding-independent weight loss and decreased adiposity, associated with increased sympathetic tone, brown adipose tissue (BAT) thermogenesis and browning of white adipose tissue (WAT).Conclusion: Overall, this evidence indicates that specific modulation of hypothalamic AMPK using a sEV-based technology may be a suitable strategy against genetic forms of obesity, such as LEPR deficiency
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function

  • Lima, Nátalia da Silva
  • Fernández Fondevila, Marcos
  • Novoa Deaño, Eva María
  • Buqué, Xabier
  • Mercado Gómez, María
  • Gallet, Sarah
  • González Rellán, María Jesús
  • Fernández Paz, Uxía
  • Loyens, Anne
  • García Vence, María
  • Chantada Vázquez, María del Pilar
  • Bravo López, Susana Belén
  • Marañón Barnusell, Patricia
  • Senra Viñas, Ana
  • Escudero Pérez, Adriana
  • Leiva Arjona, Magdalena
  • Guallar Artal, Diana
  • Fidalgo Pérez, Miguel Ángel
  • Gomes, Pedro
  • Claret, Marc
  • Sabio Buzo, Guadalupe
  • Varela Rey, Marta María
  • Cardoso Delgado, Teresa
  • Montero Vallejo, Rocío
  • Ampuero, Javier
  • López Pérez, Miguel A.
  • Diéguez González, Carlos
  • Herrero, Laura
  • Serra Cucurull, Dolors
  • Schwaninger, Markus
  • Prevot, Vincent
  • Gallego-Durán, Rocío
  • Romero-Gómez, Manuel
  • Iruzubieta, Paula
  • Crespo García, Javier
  • Martínez Chantar, María Luz
  • García Monzón, Carmelo
  • González-Rodríguez, Águeda
  • Aspichueta, Patricia
  • Nogueiras Pozo, Rubén
Non-alcoholic fatty liver disease (NAFLD) is a major health threat in both developed and developing countries and is a precursor of the more advanced liver diseases, including non-alcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. Currently, understanding the multiple and complex molecular pathways implicated in NAFLD onset and progression is a major priority. The transcription factor p63, which belongs to a family comprising p53, p63, and p73,1 is one of many factors that contributes to the development of liver steatosis. The role of p63 as a tumor suppressor and in cell maintenance and renewal is well studied, but we have recently reported that it is also relevant in the control of lipid metabolism.2 p63 encodes multiple isoforms that can be grouped into 2 categories; isoforms with an acidic transactivation domain (TA) and those without this domain (domain negative). The TAp63α isoform is elevated in the liver of animal models of NAFLD as well as in liver biopsies from obese patients with NAFLD. Furthermore, downregulation of p63α in the liver attenuates liver steatosis in diet-induced obese (DIO) mice, while the activation of TAp63α increases hepatic fat content, mediated by the activation of IKKβ and endoplasmic reticulum stress.2 A specialized form of autophagy that degrades lipid droplets, termed “lipophagy”, is a major pathway of lipid mobilization in hepatocytes. Lipophagy is elevated in hepatoma cells upon exposure to free fatty acids,3 and reduces the fatty acid load in mouse hepatocytes.4 Its impairment has been associated with the development of fatty liver and insulin resistance3,5; in contrast, the autophagic flux is increased during the activation of hepatic stellate cells.6 In the present study, we used an unbiased proteomics approach to gain insight into novel proteins modulating lipid metabolism in the liver of mice with genetic knockdown or overexpression of TAp63α. We found that autophagy-related gene 3 (ATG3) was upregulated by TAp63α activation and downregulated after p63α inhibition. ATG3 is elevated in several animal models of NAFLD and in the liver of patients with NAFLD. Genetic overexpression of ATG3 increased the lipid load in hepatocytes, while its repression alleviated TAp63α- and diet-induced steatosis. ATG3 exerted its role in lipid metabolism by regulating SIRT1 and mitochondrial function. Collectively, these findings identify ATG3 as a novel factor implicated in the development of steatosis
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Temperature modulates systemic and central actions of thyroid hormones on BAT thermogenesis

  • Rial-Pensado, Eva
  • Rivas, Verónica
  • Grijota Martínez, María del Carmen
  • Rodríguez-Díaz, Amanda
  • Capelli, Valentina
  • Barca-Mayo, Olga
  • Nogueiras, Rubén
  • Mittag, Jens
  • Diéguez, Carlos
  • López, Miguel
Thyroid hormones (THs) play a major role regulating energy balance and brown adipose tissue (BAT) thermogenesis, as well as body temperature, as shown in hyperthyroid patients. However, the current landscape of preclinical thyroid hormone models is complex. For example, while rats become catabolic after TH administration, mice gain weight; so, these differences in species need to be analyzed in detail and specially whether temperature could be a factor. Here, we aimed to investigate the effect of environmental temperature on those actions. Rats were subcutaneously treated with L-thyroxine (T4) or stereotaxically within the ventromedial nucleus of the hypothalamus (VMH) with triiodothyronine (T3) and housed at 23°C, 4°C or 30°C; energy balance, BAT thermogenesis and AMP-activated protein kinase (AMPK) in the VMH were analyzed. Our data showed that the effect of both systemic T4 of central T3 on energy balance and BAT thermogenesis was dependent upon environmental temperature. This evidence is of interest in the design of experimental settings highlighting the species-specific metabolic actions of THs, and in understanding its physiological role in the adaptation to temperature., This research was funded by: Ministerio de Ciencia y Universidades co-funded by the FEDER Program of EU (CD: BFU 2017-87721; RN: RTI 2018-099413-B-I00 and RED 2018-102379-T; ML: RTI 2018-101840-B-I00, PID2021-128145NB-I00 and PDC2022-133958-I00). “la Caixa” Foundation (ID100010434), under the agreement LCF/PR/HR19/52160022 (ML); European Research Council (RN: ERC Synergy Grant-2019-WATCH- 810331).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function

  • Lima, Natália da Silva
  • Fondevila, Marcos F.
  • Nóvoa, Eva
  • Buqué, Xabier
  • Mercado-Gómez, María
  • Gallet, Sarah
  • González-Rellán, María Jesús
  • Fernández, Uxía
  • Loyens, Anne
  • García-Vence, María
  • Chantada-Vázquez, María del Pilar
  • Bravo, Susana Belén
  • Marañón, Patricia
  • Senra, Ana
  • Escudero, Adriana
  • Leiva, Magdalena
  • Guallar, Diana
  • Fidalgo, Miguel
  • Gomes, Pedro
  • Claret, Marc
  • Sabio, Guadalupe
  • Varela-Rey, Marta
  • Delgado, Teresa C.
  • Montero-Vallejo, Rocío
  • Ampuero, Javier
  • López, Miguel
  • Diéguez, Carlos
  • Herrero, Laura
  • Serra, Dolors
  • Schwaninger, Markus
  • Prevot, Vincent
  • Gallego-Durán, Rocío
  • Romero-Gómez, Manuel
  • Iruzubieta, Paula
  • Crespo, Javier
  • Martínez-Chantar, María Luz
  • García-Monzón, Carmelo
  • González-Rodríguez, Águeda
  • Aspichueta, Patricia
  • Nogueiras, Rubén
[Background & Aims] Autophagy-related gene 3 (ATG3) is an enzyme mainly known for its actions in the LC3 lipidation process, which is essential for autophagy. Whether ATG3 plays a role in lipid metabolism or contributes to non-alcoholic fatty liver disease (NAFLD) remains unknown., [Methods] By performing proteomic analysis on livers from mice with genetic manipulation of hepatic p63, a regulator of fatty acid metabolism, we identified ATG3 as a new target downstream of p63. ATG3 was evaluated in liver samples from patients with NAFLD. Further, genetic manipulation of ATG3 was performed in human hepatocyte cell lines, primary hepatocytes and in the livers of mice., [Results] ATG3 expression is induced in the liver of animal models and patients with NAFLD (both steatosis and non-alcoholic steatohepatitis) compared with those without liver disease. Moreover, genetic knockdown of ATG3 in mice and human hepatocytes ameliorates p63- and diet-induced steatosis, while its overexpression increases the lipid load in hepatocytes. The inhibition of hepatic ATG3 improves fatty acid metabolism by reducing c-Jun N-terminal protein kinase 1 (JNK1), which increases sirtuin 1 (SIRT1), carnitine palmitoyltransferase 1a (CPT1a), and mitochondrial function. Hepatic knockdown of SIRT1 and CPT1a blunts the effects of ATG3 on mitochondrial activity. Unexpectedly, these effects are independent of an autophagic action., [Conclusions] Collectively, these findings indicate that ATG3 is a novel protein implicated in the development of steatosis., This work has been supported by grants from FEDER/Ministerio de Ciencia, Innovación y Universidades-Agencia Estatal de Investigación (PA: RTI2018-095134-B-100; DS and LH: SAF2017-83813-C3-1-R; MLMC: RTC2019-007125-1; CD: BFU2017-87721; ML: RTI2018–101840-B-I00; GS; PID2019-104399RB-I00; RN: RTI2018-099413-B-I00 and RED2018-102379-T; MLMC: SAF2017-87301-R; TCD: RTI2018-096759-A-100), FEDER/Instituto de Salud Carlos III (AGR: PI19/00123), Xunta de Galicia (ML: 2016-PG068; RN: 2015-CP080 and 2016-PG057), Fundación BBVA (RN, GS and MLM), Proyectos Investigación en Salud (MLMC: DTS20/00138), Sistema Universitario Vasco (PA: IT971-16); Fundación Atresmedia (ML and RN), Fundación La Caixa (M.L., R.N. and M.C.), Gilead Sciences International Research Scholars Program in Liver Disease (MVR), Marató TV3 Foundation (DS: 201627), Government of Catalonia (DS: 2017SGR278) and European Foundation for the Study of Diabetes (RN and GS). This research also received funding from the European Community’s H2020 Framework Programme (ERC Synergy Grant-2019-WATCH- 810331, to RN, VP and MS). Centro de Investigación Biomédica en Red (CIBER) de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Hepáticas y Digestivas (CIBERehd) and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem). CIBERobn, CIBERehd and CIBERdem are initiatives of the Instituto de Salud Carlos III (ISCIII) of Spain which is supported by FEDER funds. We thank MINECO for the Severo Ochoa Excellence Accreditation to CIC bioGUNE (SEV-2016-0644)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neddylation of phosphoenolpyruvate carboxykinase 1 controls glucose metabolism

  • Gonzalez-Rellan, María J
  • Fernández, Uxía
  • Parracho, Tamara
  • Novoa, Eva
  • Fondevila, Marcos F
  • da Silva Lima, Natalia
  • Ramos, Lucía
  • Rodríguez, Amaia
  • Serrano-Maciá, Marina
  • Pérez-Mejías, Gonzalo
  • Chantada-Vazquez, Pilar
  • Riobello, Cristina
  • Veyrat-Durebex, Christelle
  • Tovar, Sulay
  • Coppari, Roberto
  • Woodhoo, Ashwin
  • Schwaninger, Markus
  • Prevot, Vincent
  • Delgado, Teresa C.
  • Lopez, Miguel
  • Díaz-Quintana, Antonio
  • Dieguez, Carlos
  • Guallar, Diana
  • Frühbeck, Gema
  • Díaz-Moreno, Irene
  • Bravo, Susana B
  • Martinez-Chantar, Maria L
  • Nogueiras, Ruben
Neddylation is a post-translational mechanism that adds a ubiquitin-like protein, namely neural precursor cell expressed developmentally downregulated protein 8 (NEDD8). Here, we show that neddylation in mouse liver is modulated by nutrient availability. Inhibition of neddylation in mouse liver reduces gluconeogenic capacity and the hyperglycemic actions of counter-regulatory hormones. Furthermore, people with type 2 diabetes display elevated hepatic neddylation levels. Mechanistically, fasting or caloric restriction of mice leads to neddylation of phosphoenolpyruvate carboxykinase 1 (PCK1) at three lysine residues-K278, K342, and K387. We find that mutating the three PCK1 lysines that are neddylated reduces their gluconeogenic activity rate. Molecular dynamics simulations show that neddylation of PCK1 could re-position two loops surrounding the catalytic center into an open configuration, rendering the catalytic center more accessible. Our study reveals that neddylation of PCK1 provides a finely tuned mechanism of controlling glucose metabolism by linking whole nutrient availability to metabolic homeostasis., This work was supported by grants from: FEDER/Ministerio de Ciencia, Innovación y Universidades-Agencia Estatal de Investigación (M.L.M.-C.: PID2020-117116RB-I00; C.D.: BFU2017-87721; M.L.: RTI2018-101840-B-I00; R.N.: PID2021-126096NB-I00 and RED2018-102379-T); Xunta de Galicia (R.N.: 2021-CP085 and 2020-PG0157); Fundación BBVA (to R.N.); Subprograma Retos Colaboración RTC2019-007125-1 (to M.L.M.-C.); Proyectos Investigación en Salud DTS20/00138 (to M.L.M.-C.); Proyectos Investigación en Salud (M.L.M.-C.: DTS20/00138); Fundación Atresmedia (to M.L. and R.N.); and Fundación La Caixa (to M.L., M.L.M.-C., and R.N.). This research also received funding from the European Community’s H2020 Framework Programme (ERC Synergy Grant-2019-WATCH- 810331, to R.N., V.P., and M.S.). The Centro de Investigación Biomédica en Red (CIBER) de Fisiopatología de la Obesidad y Nutrición (CIBERobn) and the Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Hepáticas y Digestivas (CIBERehd) are initiatives of the Instituto de Salud Carlos III (ISCIII) of Spain, which is supported by FEDER funds. We thank MINECO for the Severo Ochoa Excellence Accreditation bioGUNE (SEV-2016-0644) to CIC., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

JNK1 in SF1 neurons regulates the central action of thyroid hormones on hepatic lipid metabolism

  • Fernández-González, Iara
  • Freire-Agulleiro, Oscar
  • Ferreira, Vitor
  • Silveira-Loureiro, María
  • Rial-Pensado, Eva
  • Garrido-Gil, Pablo
  • Martínez, Gloria
  • Rada, Patricia
  • Labandeira-Garcia, Jose Luis
  • Mittag, Jens
  • González-García, Ismael
  • Diéguez, Carlos
  • Nogueiras, Rubén
  • Valverde, Ángela M.
  • Davis, Roger J.
  • Sabio, Guadalupe
  • Barca-Mayo, Olga
  • López, Miguel
[Objective] Hypothalamic energy sensors, such as AMP-activated protein kinase (AMPK), and stress sensors, such as c-Jun N-terminal kinase 1 (JNK1, also known as MAPK8) modulate whole body energy balance. While the role of AMPK in steroidogenic factor 1 (SF1) neurons of the VMH has been investigated, the relevance of JNK1 in this neuronal population has not been addressed. Here, we investigated the involvement of JNK1 SF1 on energy homeostasis., [Methods] We generated mice bearing conditional JNK1 disruption through Mapk8 gene deletion in SF1 neurons (Sf1Cre/Jnk1fl/fl). Complete metabolic phenotyping, fasting/refeeding and cold challenges, as well as the central response to triiodothyronine (T3) on brown adipose tissue (BAT) thermogenesis and hepatic lipid metabolism were carried out., [Results] Sf1Cre/Jnk1fl/fl mice displayed decreased body weight, improved glucose tolerance, and reduced hepatic lipid levels. However, Sf1Cre/Jnk1fl/fl did not properly defend their temperature upon cold exposure. While central administration of T3 elicited feeding independent weight loss in both wildtype (Jnk1fl/fl) and SF1Cre/Jnk1fl/fl mice, it did not promote hepatic lipid accretion in null animals., [Conclusions] Our data demonstrated for the first time that JNK1 in SF1 neurons is necessary for the regulation of hepatic lipid metabolism, cold adaptation and central T3 actions., The research leading to these results has received funding from the Xunta de Galicia (IG-G: ED431F 2024/14; IG-G and RN ED431C 2024/10; RN: 2016-PG057; OB-M: ED431F 2020/009 and ED431C 2023/28); Ministerio de Ciencia e Innovación co-funded by the FEDER Program of EU (IG-G: PID2022-141115NA-I00; CD: PID2020-116628 GB-I00; RN: RTI2018-099413-B-I00 and RED2018-102379-T; AM-V; PID2021-122766OB-100; GS: PID2019-104399RB-I00; PMP21/00057; PDC2021-121147-I00 IMPACT-202; OB-M: PID2019-109556RB-I00; PID2022-138436OB-I00; ML: PID2021-128145NB-I00 and PDC2022-133958-I00); European Research Council (RN: ERC Synergy Grant-2019-WATCH- 810331); “la Caixa” Foundation (ID 100010434), (ML: LCF/PR/HR19/52160022 and LCF/PR/HR20/52400013); Fundación AECC (GS: PROYE19047SABI; ML: PRYGN234908LOPE). IG-G and OB-M are supported by Ramón y Cajal Awards (IG-G: RYC2021-031225-I; OB-M: RYC2018-026293-I) from the Ministerio de Ciencia e Innovación of Spain. OF-A was supported by a fellowship from Xunta de Galicia (ED481A-2019/026). CiMUS was supported by the Xunta de Galicia (2020–2023, ED431G/05). CIBER de Fisiopatología de la Obesidad y Nutrición, CIBER de Diabetes y Enfermedades Metabólicas Asociadas and CIBER de Enfermedades Neurodegenerativas are initiatives of ISCIII., Peer reviewed